Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists

Findings Correlate with Positive Phase 1 Safety Data for ANAVEX 2-73 New York, NY — March 4, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences.  Among its conclusions, the report reveals…